Heparan sulfate accumulation with Aβ deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells

Brain Pathology

Volumn 18, Issue 4, 2008, Pages 548-561

  O'Callaghan, Paul ^a   Sandwall, Elina ^b   Li, Jin Ping ^b   Yu, Hong ^c   Ravid, Rivka ^e   Guan, Zhi Zhong ^d   Van Kuppevelt, Toin H ^f   Nilsson, Lars N G ^a   Ingelsson, Martin ^a   Hyman, Bradley T ^g   Kalimo, Hannu ^a   Lindahl, Ulf ^b   Lannfelt, Lars ^a   Zhang, Xiao ^a,h  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NETHERLANDS BRAIN BANK   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UPPSALA UNIVERSITY   (Sweden)

Author keywords

Glial cells; Heparan sulfate; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYPICAN 1; HEPARAN SULFATE; PRESENILIN 1; PROTEOHEPARAN SULFATE; SYNDECAN 3;

AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GLIA CELL; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; WESTERN BLOTTING;

EID: 51249091645     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2008.00152.x     Document Type: Article

References (42)

1. Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 18 : 25 51.
2. Bame KJ, Danda J, Hassall A, Tumova S (1997) Abeta(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer's disease. J Biol Chem 272 : 17005 17011.
3. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68 : 729 777.
4. D'Andrea, MR, Cole GM, Ard MD (2004) The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging 25 : 675 683.
5. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, van Kuppevelt TH (2002) Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 277 : 10982 10986.
6. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108 : 169 173.
7. Fransson LA (2003) Glypicans. Int J Biochem Cell Biol 35 : 125 129.
8. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J et al (1998) The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 273 : 29719 29726.
9. Gupta-Bansal R, Frederickson RC, Brunden KR (1995) Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 270 : 18666 18671.
10. Hagino S, Iseki K, Mori T, Zhang Y, Hikake T, Yokoya S et al (2003) Slit and glypican-1 mRNAs are coexpressed in the reactive astrocytes of the injured adult brain. Glia 42 : 130 138.
11. Hagino S, Iseki K, Mori T, Zhang Y, Sakai N, Yokoya S et al (2003) Expression pattern of glypican-1 mRNA after brain injury in mice. Neurosci Lett 349 : 29 32.
12. Iseki K, Hagino S, Mori T, Zhang Y, Yokoya S, Takaki H et al (2002) Increased syndecan expression by pleiotrophin and FGF receptor-expressing astrocytes in injured brain tissue. Glia 39 : 1 9.
13. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 : 45 53.
14. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y (1995) Amyloid beta protein (A beta) deposition A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 37 : 294 299.
15. Kisilevsky R, Fraser PE (1997) A beta amyloidogenesis: unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol 32 : 361 404.
16. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA (1995) Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1 : 143 148.
17. Kreuger J, Spillmann D, Li JP, Lindahl U (2006) Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 174 : 323 327.
18. Lannfelt L, Viitanen M, Johansson K, Axelman K, Lilius L, Almqvist E, Winblad B (1993) Low frequency of the APP 670/671 mutation in familial Alzheimer's disease in Sweden. Neurosci Lett 153 : 85 87.
19. Leadbeater WE, Gonzalez AM, Logaras N, Berry M, Turnbull JE, Logan A (2006) Intracellular trafficking in neurones and glia of fibroblast growth factor-2, fibroblast growth factor receptor 1 and heparan sulphate proteoglycans in the injured adult rat cerebral cortex. J Neurochem 96 : 1189 1200.
20. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3 : 16 32.
21. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S et al (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein a amyloidosis. Proc Natl Acad Sci USA 102 : 6473 6477.
22. Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U, Salmivirta M (1999) Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem 274 : 30631 30635.
23. Maccarana M, Casu B, Lindahl U (1994) Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 269 : 3903.
24. Mann DM, Takeuchi A, Sato S, Cairns NJ, Lantos PL, Rossor MN et al (2001) Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as "cotton wool" plaques. Neuropathol Appl Neurobiol 27 : 189 196.
25. Mark RJ, Keller JN, Kruman I, Mattson MP (1997) Basic FGF attenuates amyloid beta-peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na+/K+-ATPase activity in hippocampal neurons. Brain Res 756 : 205 214.
26. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE (1999) Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem 266 : 1101 1110.
27. McNamara MJ, Gomez-Isla T, Hyman BT (1998) Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 55 : 1001 1004.
28. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1 : 345 347.
29. Saura J, Tusell JM, Serratosa J (2003) High-yield isolation of murine microglia by mild trypsinization. Glia 44 : 183 189.
30. Schofield KP, Gallagher JT, David G (1999) Expression of proteoglycan core proteins in human bone marrow stroma. Biochem J 343 : 663 668.
31. Selkoe DJ (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 924 : 17 25.
32. Selkoe DJ (2001) Alzheimer's disease: genes proteins and therapy. Physiol Rev 81 : 741 766.
33. Snow AD, Willmer J, Kisilevsky R (1987) Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest 56 : 120 123.
34. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S et al (1988) The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133 : 456 463.
35. Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K (1994) Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol 144 : 337 347.
36. Soderberg L, Bogdanovic N, Axelsson B, Winblad B, Naslund J, Tjernberg LO (2006) Analysis of single Alzheimer solid plaque cores by laser capture microscopy and nanoelectrospray/tandem mass spectrometry. Biochemistry 45 : 9849 9856.
37. Tumova S, Woods A, Couchman JR (2000) Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 32 : 269 288.
38. Van Gool D, David G, Lammens M, Baro F, Dom R (1993) Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer's and Lewy body type dementia. Dementia 4 : 308 314.
39. van Horssen J, Kleinnijenhuis J, Maass CN, Rensink AA, Otte-Holler I, David G et al (2002) Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging 23 : 537 545.
40. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM (2003) Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2 : 482 492.
41. Verkkoniemi A, Kalimo H, Paetau A, Somer M, Iwatsubo T, Hardy J, Haltia M (2001) Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 60 : 483 492.
42. Whitelock JM, Iozzo RV (2005) Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 105 : 2745 2764.